Curated News
By: NewsRamp Editorial Staff
December 11, 2025
ADAP Advocacy Exposes 340B Program Failures in New Campaign
TLDR
- ADAP Advocacy's campaign exposes how hospitals profit from 340B drug discounts instead of providing charity care, creating an opportunity to advocate for reform and accountability.
- The 340B Program requires drug manufacturers to offer discounted medications to eligible hospitals, which are then supposed to use the savings to provide charity care to low-income patients.
- Reforming the 340B Program could ensure hospitals use drug discounts to provide charity care, improving healthcare access for low-income and minority communities.
- ADAP Advocacy's commercial reveals that 69% of 340B hospitals offer below-average charity care despite receiving drug discounts intended for patient assistance.
Impact - Why it Matters
This news matters because the 340B Drug Pricing Program, established to help safety-net hospitals provide affordable care to low-income and uninsured patients, is showing significant flaws that directly affect healthcare equity. When hospitals fail to pass on drug discounts as charity care, vulnerable populations—especially minority communities and those with chronic conditions like HIV/AIDS—face higher out-of-pocket costs and reduced access to essential medications. This exacerbates existing health disparities and financial burdens, undermining public trust in healthcare systems. Reforming the program could lead to more transparent use of funds, better patient outcomes, and a stronger safety net, making it crucial for patients, advocates, and policymakers to address these issues promptly.
Summary
ADAP Advocacy, a nonprofit organization dedicated to improving access to care for people living with HIV/AIDS, has launched a provocative national campaign calling for urgent reforms to the 340B Drug Pricing Program. As part of its 340B Project, the organization aired a recent commercial that starkly highlights how many 340B-eligible hospitals are failing to provide adequate charity care to low-income patients, despite receiving significant discounts on medications from drug manufacturers. The campaign's central question—"Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?"—frames the issue as a systemic crisis where hospitals are allegedly pocketing savings instead of passing them on to vulnerable communities, with data showing that 69% of 340B disproportionate share hospitals offer charity care below the national average.
Brandon M. Macsata, CEO of ADAP Advocacy, emphasized that the program's core mission of serving poor patients through free care and financial aid is being undermined, disproportionately impacting minority communities. The "340B Too Big To Fail" advocacy campaign, running through year-end, exposes troubling trends including declining charity care, rising healthcare executive compensation, and exploding patient medical debt. To visualize these issues, ADAP Advocacy has developed an interactive map that elevates these concerning patterns, making complex data accessible to the public and policymakers alike.
The commercial is available online for viewing, and ADAP Advocacy encourages stakeholders to engage with their findings by contacting info@adapadvocacy.org. This effort aligns with the organization's broader mission to promote AIDS Drug Assistance Programs (ADAPs) and foster collaboration among advocates, healthcare providers, government agencies, patients, and pharmaceutical companies. By spotlighting these critical failures within the 340B program, ADAP Advocacy aims to drive meaningful policy changes that ensure discounted medications truly benefit those in need, rather than padding hospital profits.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, ADAP Advocacy Exposes 340B Program Failures in New Campaign
